May 5, 2010
The common shares of Arch Biopartners Inc. have been approved for listing on CNSX. The Company has 47,360,179 common shares outstanding with a public float of approximately 27.7 million shares.
Arch Biopartner's business is to acquire the rights to intellectual property produced by the established University of Calgary research programs of each Arch scientist under exclusive contract as well as fund, manage and develop the respective research projects with the goal of realizing the commercial potential of the intellectual property. The Company intends to sell developed intellectual property, technology or products to larger biotech, pharmaceutical or industrial companies. Arch will have three subsidiaries with each pursuing intellectual property related to i) anti-inflammatory small molecule and biochemical compounds, ii) peptide metal/solid surface interfacing, and iii) brain tumour stem cells.
Listing and disclosure documents for Arch Biopartners Inc. will be available in the CNSX Listings Disclosure Hall
Trading Date: Friday, May 7, 2010
CUSIP: 03938C 10 4
ISIN: CA 03938C 10 4 1
If you have any questions or require further information please contact Radhika at (416) 572-2000 X 2435 or E-mail: email@example.com